High-Risk IgVH-Unmutated Chronic Lymphocytic Leukemia

Video

High-Risk IgVH-Unmutated Chronic Lymphocytic Leukemia

Case:A 62-Year—Old Male WithIgVH-Unmutated CLL

  • A 62-year-old male presented to PCP with complaints of extreme fatigue and night sweats
  • PE: Enlarged mobile lymph nodes bilaterally (~1.5 cm), no palpable spleen or liver
  • Laboratory findings:
    • WBC; 100 X 109/L
    • Lymphocytes; 82 X 109/L
    • Hb; 11.2 g/dL
    • Platelets; 190 X 109/L
    • ANC; 1,950/mm3
    • LDH 150 U/L
  • Cytogenetic; del(11q),IgVH-unmutated
  • β2M, 2.9 mg/L
  • Referred to community oncology who diagnosed patient with chronic lymphocytic leukemia
  • Patient was started on ibrutinib + rituximab (IR)
  • Rai Stage I
Recent Videos
Related Content
FDA Approves First Oral Liquid Imatinib for Leukemia and Other Cancers

FDA Approves First Oral Liquid Imatinib for Leukemia and Other Cancers

Jordyn Sava
November 25th 2024
Article

Imatinib oral solution has gained FDA approval for the treatment of some cancers, including certain forms of leukemia.

Read More

Understanding the Role of Zanubrutinib for the Treatment of CLL

Understanding the Role of Zanubrutinib for the Treatment of CLL

Rohit Gosain, MD;Rahul Gosain, MD
April 23rd 2024
Podcast

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Listen

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Learning From a Multidisciplinary Approach in Graft-Vs-Host Disease

Jonah Feldman
November 15th 2024
Article

In this feature, Memorial Sloan Kettering Cancer Center physicians explain what drives the collaborative process in their multidisciplinary graft-vs-host disease clinic.

Read More

Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

Nichole Tucker;Cyrus M. Khan, MD
May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Morgan Bayer
November 14th 2024
Article

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

Read More

Advancements in CLL: CAR T, BTK Inhibitors and Personalized Medicine

Advancements in CLL: CAR T, BTK Inhibitors and Personalized Medicine

Jordyn Sava
November 13th 2024
Article

Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the availability of CAR T-cell therapy.

Read More